Glucotoxicity-induced suppression of Cox6a2 expression provokes β-cell dysfunction via augmented ROS production

Yasuki Nagai1, Taka-Aki Matsuoka2, Naoki Shimo1

  • 1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan.

Insights

Decreased Cox6a2 expression in pancreatic cells elevates oxidative stress, impairing glucose tolerance in diabetes. MafA transcription factor directly regulates Cox6a2, suggesting a mechanism for beta-cell dysfunction.

Area of Science:

  • Cellular biology
  • Mitochondrial function
  • Diabetes mellitus research

Background:

  • Oxidative stress damages pancreatic beta-cells in diabetes.
  • The precise molecular mechanisms driving this oxidative stress are not fully understood.
  • Previous work indicated Cox6a2 downregulation under glucotoxicity.

Purpose of the Study:

  • To investigate the role of Cox6a2 in pancreatic beta-cell function.
  • To elucidate the pathophysiological significance of Cox6a2 in diabetes mellitus.
  • To identify the transcriptional regulation of Cox6a2.

Main Methods:

  • Cox6a2 knockdown in MIN6-CB4 cells.
  • Reactive oxygen species detection using CellROX Deep Red reagent and flow cytometry.
  • Analysis of Cox6a2-knockout mice fed a high-fat, high-sucrose diet.
  • ATAC-seq on islet DNA and reporter gene assays.

Main Results:

  • Cox6a2 knockdown increased reactive oxygen species production.
  • Cox6a2-knockout mice exhibited impaired glucose tolerance.
  • MafA was identified as a direct regulator of Cox6a2 expression.
  • MafA is linked to reduced Cox6a2 expression under glucotoxic conditions.

Conclusions:

  • Reduced Cox6a2 expression contributes to increased reactive oxygen species in beta-cells.
  • MafA directly regulates Cox6a2, implicating it in beta-cell dysfunction during diabetes.
  • Findings highlight Cox6a2 as a potential target for managing diabetic complications.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
5.4K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
14.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
538
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
416
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
511